Related Experiment Video

Updated: Feb 22, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K

MEK inhibition and immune responses in advanced melanoma

Reinhard Dummer1, Egle Ramelyte1, Sabrina Schindler1

  • 1University Hospital Zurich, Department Dermatology, Zürich, Switzerland.

Oncoimmunology
|September 19, 2017
PubMed

Insights

Binimetinib showed modest anti-tumor activity in NRAS mutant melanoma. Pre-treatment with immunotherapy improved outcomes when combined with binimetinib therapy, particularly in NRAS-mutant melanoma.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Binimetinib (MEK162) is a MEK1/2 inhibitor with modest anti-tumor activity in advanced NRAS-mutant melanoma.
  • NRAS mutations are a key driver in a subset of melanoma patients.

Purpose of the Study:

  • To analyze the impact of pre-treatment with immunotherapy on binimetinib efficacy in NRAS-mutant melanoma patients within the NEMO study.
  • To explore the in vitro and in vivo effects of MEK inhibition on immune pathways.

Main Methods:

  • Analysis of clinical trial data from the NEMO study.
  • In vitro and in vivo experimental models to assess MEK inhibition effects on immuno-critical pathways.

Main Results:

  • Binimetinib demonstrated modest anti-tumor activity in advanced NRAS-mutant melanoma.
  • Pre-treatment with immunotherapy significantly improved outcomes for patients receiving binimetinib therapy.

Conclusions:

  • Combining immunotherapy with binimetinib may enhance treatment efficacy in NRAS-mutant melanoma.
  • MEK inhibition influences key immune interactions, warranting further investigation in combination therapies.
Keywords:
BRAF mutationMEK inhibitorsMEK kinase pathwayMelanomaNRAS mutationimmunogenicityimmunotherapy

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.6K

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K